NCIC CLINICAL TRIALS GROUP

BRAIN

DISEASE SITE COMMITTEE MEETING AGENDA

Delta Chelsea Hotel, Toronto, Ontario Sunday, April 18, 2004 - 8:30 a.m. - 12:00 p.m. Room: Mountbatten Salon A

Chairs: J. Gregory Cairncross, Warren Mason

8:30 a.m.	Welcome and Introductions	G Cairncross
COMPLETED STUDIES		
8:40 a.m.	IND.139-T138067 Na-manuscript status	S Kirby
8:45 a.m.	IND.142 – SarCNU in malignant glioma	G Cairncross
8:50 a.m.	CE.2-PCV plus RT vs RT for oligodendroglioma Results	G Cairncross
9:15 a.m.	CE.3-Temozolomide plus RT vs RT for GBM Results Tissue Microarray and Research	W Mason
New Trials		
9:45 a.m.	CE.4-RT vs observation for incompletely resected benign meningiom Protocol overview, discussion, timelines	a R Del Maestro / L Souhami
10:00 am	CE.5-RT vs Temozolomide for low-grade glioma Protocol overview, discussion, central procedures	W Mason / D Rheaume
10:30 a.m.	COFFEE BREAK	
FUTURE NCIC PHASE I/II STUDIES		
10:45 a.m.	IND.162-A phase I/II study of RAD001c plus Temozolomide in GBM	W Mason
11:00 a.m.	IND.170- A phase I/II study of GW572016 in GBM	B Thiessen
11:30 a.m.	Report from the NCIC CTG IND meeting	W Mason
IDEAS FOR NEW GBM TRIALS		
11:45 a.m.	Trials for elderly GBM	N Laperriere / J Perry

12:00 p.m. **ADJOURN**